Physician profile
Stella Taber
NPI 1639723489
$6,212.34
in general payments reported to CMS, 2019-2025
37 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $782 · 2022: $1,256 · 2023: $1,329 · 2024: $1,494 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,987 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,986.96 |
| Education | $187.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,225.27 | 2021-2025 | Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $1,072.92 | 2021-2025 | |
| Amgen INC. | $661.99 | 2021-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $383.21 | 2023-2025 | Uptravi, Opsumit |
| Abbott Laboratories | $355.21 | 2024-2025 | Cardiomems, Diamondback Peripheral |
| Janssen Pharmaceuticals, INC | $317.62 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $302.44 | 2022-2024 | Watchman Flx, Watchman Access System, Ekosonic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.77 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $207.21 | 2022-2025 | Verquvo, Winrevair |
| Astellas Pharma US INC | $206.27 | 2022 | |
| Esperion Therapeutics, INC. | $139.92 | 2021-2023 | Nexletol |
| Pfizer INC. | $120.11 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $107.76 | 2022-2025 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $88.07 | 2022-2025 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $85.17 | 2024 | Arcalyst |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $81.14 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $68.70 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.64 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $51.08 | 2023 | Onpattro |
| Angiodynamics, INC. | $38.71 | 2023-2024 | Alphavac |
| Ethicon US, LLC | $35.30 | 2025 | Ethicon, Vistaseal, Surgiflo Hemostatic Matrix |
| Imperative Care, INC | $25.49 | 2025 | Symphony Catheter |
| Shockwave Medical, INC | $25.30 | 2025 | |
| Abiomed | $25.14 | 2025 | |
| Kestra Medical Technology Services, INC. | $23.26 | 2025 | Assure Wcd |
| Teleflex LLC | $23.07 | 2025 | Guideliner |
| Recor Medical INC | $23.05 | 2024 | Paradise Renal Denervation System |
| Glaxosmithkline, LLC. | $21.16 | 2025 | Arexvy, Shingrix |
| Chiesi USA, INC. | $20.91 | 2022 | |
| Novo Nordisk INC | $20.75 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.88 | 2023 | Lifevest |
| Medtronic, INC. | $17.86 | 2023 | Linq II |
| Terumo Medical Corporation | $17.20 | 2023 | Tr Band |
| Cardiovascular Systems INC. | $15.69 | 2021 | |
| Bard Peripheral Vascular, INC. | $15.56 | 2024 | Fluency Endovascular Stent Graft |
| Kiniksa Pharmaceuticals, LTD. | $14.02 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $13.49 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Taber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.